Investor Relations

Message from the
Chairman and CEO

We are working to meet the expectations of our shareholders and investors by enhancing corporate value.

Business Results for the First Six Months of the Fiscal Year Ending March 31, 2019

IR Information

Press Releases ＞IR Topics ＞

Dec. 04, 2018: With a View to New Value Creation, Sysmex Launches a Research Assay Service for HDL Function Measurement
-Aiming to Prevent Atherosclerosis-Related Diseases and Provide Treatment Opportunities-
Dec. 04, 2018: Sysmex Wins the Encouragement Prize for the First Time in the 6th WICI Japan Award for Excellence in Integrated Reporting
Dec. 03, 2018: Sysmex Launches Revohem FIX Chromogenic, a Blood Coagulation Factor IX Measurement Kit
-Japan’s First Coagulation Factor IX Measurement Kit Using Chromogenic Assay, Helping to Diagnose and Assist in the Treatment of Hemophilia B-
Nov. 28, 2018: Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization
-To Accelerate Precision Medicine Through Globally Proven Experience-
Nov. 13, 2018: Sysmex Launches Single Molecule Fluorescence Microscope HM-1000 for Research Use
-Supporting R&D Related to New Therapeutic Drugs and Diagnostic Methods with a Super-Resolution Fluorescence Microscope Having High Spatial Resolution-

Press Releases IR Topics